Healthcare -
Biotechnology - NASDAQ - US
$ 3.49
-1.41 %
$ 1.82 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Revelation Biosciences, Inc.
| Current Assets | 12.1 M |
| Cash & Short-Term Investments | 12 M |
| Receivables | 0 |
| Other Current Assets | 156 K |
| Non-Current Assets | 65.1 K |
| Long-Term Investments | 0 |
| PP&E | 65.1 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 5.56 M |
| Accounts Payable | 1.36 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 4.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Revelation Biosciences, Inc.
| Revenue | 0 |
| Cost Of Revenue | 25 K |
| Gross Profit | -25 K |
| Operating Expenses | 8.66 M |
| Operating Income | -8.66 M |
| Other Expenses | -8.54 M |
| Net Income | -120 K |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Revelation Biosciences, Inc.
| Net Income | -120 K |
| Depreciation & Amortization | 25 K |
| Capital Expenditures | -4 |
| Stock-Based Compensation | 156 K |
| Change in Working Capital | 982 K |
| Others | -8.1 M |
| Free Cash Flow | -7.29 M |
Wall Street Analysts Price Targets
Revelation Biosciences, Inc.
REVB has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
REVB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Revelation Biosciences, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Dec 08, 2023
|
Sell 14.4 K
USD
|
TIDMARSH GEORGE F
Director
|
- 27771
|
0.5199 USD |
|
1 year ago
Oct 16, 2023
|
Sell 1.2 K
USD
|
TIDMARSH GEORGE F
Director
|
- 1845
|
0.6501 USD |
|
1 year ago
Oct 16, 2023
|
Sell 7.24 K
USD
|
TIDMARSH GEORGE F
Director
|
- 10957
|
0.661 USD |
|
1 year ago
Sep 28, 2023
|
Sell 986
USD
|
TIDMARSH GEORGE F
Director
|
- 1429
|
0.69 USD |
|
1 year ago
Sep 14, 2023
|
Sell 9 K
USD
|
TIDMARSH GEORGE F
Director
|
- 12000
|
0.75 USD |
|
1 year ago
Sep 15, 2023
|
Sell 6.94 K
USD
|
TIDMARSH GEORGE F
Director
|
- 9500
|
0.73 USD |
|
1 year ago
Sep 18, 2023
|
Sell 2.96 K
USD
|
TIDMARSH GEORGE F
Director
|
- 4000
|
0.74 USD |
|
1 year ago
Apr 18, 2023
|
Bought
29 K USD
|
TIDMARSH GEORGE F
Director
|
+ 25000
|
1.16 USD |
|
1 year ago
Apr 17, 2023
|
Bought
30.7 K USD
|
TIDMARSH GEORGE F
Director
|
+ 26500
|
1.16 USD |
|
3 years ago
Feb 25, 2022
|
Bought
32 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 20000
|
1.6 USD |
|
3 years ago
Feb 09, 2022
|
Bought
76.6 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 30000
|
2.5533 USD |
|
3 years ago
Feb 08, 2022
|
Bought
2.54 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 1000
|
2.54 USD |
|
3 years ago
Feb 07, 2022
|
Bought
110 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 42100
|
2.6076 USD |
|
3 years ago
Feb 04, 2022
|
Bought
18.3 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 7900
|
2.3109 USD |
|
3 years ago
Feb 04, 2022
|
Bought
4.9 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 2000
|
2.45 USD |
|
3 years ago
Feb 07, 2022
|
Bought
110 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 42100
|
2.6076 USD |
|
3 years ago
Feb 04, 2022
|
Bought
18.3 K USD
|
TIDMARSH GEORGE F
director, 10 percent owner:
|
+ 7900
|
2.3109 USD |
|
3 years ago
Sep 21, 2021
|
Sell 433 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 43000
|
10.08 USD |
|
3 years ago
Sep 22, 2021
|
Sell 50.4
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 5
|
10.08 USD |
|
3 years ago
Sep 23, 2021
|
Sell 6.16 M
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 611541
|
10.08 USD |
|
4 years ago
Nov 09, 2020
|
Sell 50 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 5000
|
10 USD |
|
4 years ago
Oct 09, 2020
|
Sell 93.3 K
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 9328
|
10 USD |
|
4 years ago
Oct 12, 2020
|
Sell 200
USD
|
GLAZER CAPITAL, LLC
10 percent owner
|
- 20
|
10 USD |
7. News
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under.
businesswire.com
- 1 month ago
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US based multi-site placeb.
businesswire.com
- 1 month ago
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc.
businesswire.com
- 1 month ago
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the Nasdaq Hearings Panel issued a decision letter granting Revelation's request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025.
businesswire.com
- 1 month ago
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
SAN DIEGO--(BUSINESS WIRE)---- $REVB #REVB--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 (the “Existing Warrants”), at the exercise.
businesswire.com
- 2 months ago
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the potent.
businesswire.com
- 3 months ago
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) ap.
businesswire.com
- 3 months ago
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei.
businesswire.com
- 3 months ago
Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from.
businesswire.com
- 5 months ago
How an Election Impacts Penny Stocks
Elections can significantly influence financial markets, including the domain of penny stocks. Penny stocks, often traded below five dollars per share, present a unique opportunity for investors aiming for substantial gains through small initial investments.
pennystocks.com
- 8 months ago
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
businesswire.com
- 8 months ago
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy.
businesswire.com
- 8 months ago
8. Profile
Summary
Revelation Biosciences, Inc. REVB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 1.82 M
Dividend Yield
0.00%
Description
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Contact
4660 La Jolla Village Drive, San Diego, CA, 92122
https://www.revbiosciences.com
IPO
Date
Nov. 17, 2020
Employees
9
Officers
Mr. Chester Stanley Zygmont III
Chief Financial Officer & Corporate Secretary
Ms. Carol Odle
Senior Director of Clinical Projects
Mr. James M. Rolke
Chief Executive Officer & Director
Ms. Sandra Vedrick
Vice President of Human Resources & Investor Relations